title: Neovascular age-related macular degeneration: individualizing therapy in the era of anti-angiogenic treatments.
abstract: The treatment of neovascular age-related macular degeneration (AMD) had been revolutionized by the use of anti-vascular endothelial growth factor (VEGF) drugs: bevacizumab and ranibizumab. With the introduction of a third anti-VEGF drug, aflibercept, ophthalmologists have several options to choose from, as well as various treatment regimens they can follow. In this Interview, Jeffrey S. Heier, MD, of Ophthalmic Consultants of Boston, Massachusetts, discusses his approaches to managing the treatment of patients with AMD and providing them with individualized care.
authors: Jeffrey S
authors: JS
authors: Heier
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D057285:Precision Medicine; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D011993:Recombinant Fusion Proteins; D042442:Vascular Endothelial Growth Factors; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab